241800-98-6 Usage
Description
Zoniporide, also known as Zoniporide hydrochloride hydrate, is a pharmaceutical compound that has been studied for its potential applications in various medical and scientific fields. It is known for its ability to inhibit the sodium-hydrogen exchanger isoform 1 (NHE-1) and has been investigated for its effects on certain viruses and in cytotoxicity assays.
Uses
Used in Pharmaceutical Research:
Zoniporide is used as an inhibitor of the sodium-hydrogen exchanger isoform 1 (NHE-1) for studying its effects on various physiological processes and potential therapeutic applications in rat models.
Used in Cytotoxicity Assays:
Zoniporide is utilized as a test compound in cytotoxicity assays to evaluate its potential toxic effects on cells and to determine its safety and efficacy in various experimental settings.
Used in Virology Research:
In the field of virology, Zoniporide is used to study its impact on the multiplication of the lymphocytic choriomeningitis virus, which can provide insights into the development of antiviral treatments and understanding the virus's replication mechanisms.
Biochem/physiol Actions
Zoniporide is a potent and selective inhibitor of Na+/H+ exchanger isoform 1 (NHE-1). IC50 = 59 nM at NHE-1, vs. 12,000 nM at NHE-2; Zoniporide inhibits NHE-1-dependent Na+ update with IC50 of 14 nM.
Check Digit Verification of cas no
The CAS Registry Mumber 241800-98-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,1,8,0 and 0 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 241800-98:
(8*2)+(7*4)+(6*1)+(5*8)+(4*0)+(3*0)+(2*9)+(1*8)=116
116 % 10 = 6
So 241800-98-6 is a valid CAS Registry Number.
InChI:InChI=1/C17H16N6O/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13/h1-5,8-10H,6-7H2,(H4,18,19,22,24)
241800-98-6Relevant articles and documents
COMPOUNDS FORTREATMENT OF CARDIOVASCULAR DISEASES
-
Page/Page column 40-41, (2008/06/13)
Pharmaceutical compositions containing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors in combination with Ca 2+ overload inhibitors, and the use of such combination inhibitors to treat, for example, cardiovascular disease, such as ischemia, particularly, perioperative myocardial ischemic injury in mammals, including humans, are disclosed.
Treatment of diabetes and diabetic complications with NHE-1 inhibitors
-
, (2008/06/13)
This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.
Method for preparing sodium-hydrogen exchanger type 1 inhibitor
-
, (2008/06/13)
Methods of preparing NHE-1 disclosed. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
